Fintel on MSN17h
Needham Downgrades Biogen (BIIB)Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback